MedTrace Logo

Plasmodium Falciparum Genomic Intelligence in Mozambique

NCT05306067 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 21848

Last updated 2024-08-27

No results posted yet for this study

Summary

Mozambique is among the ten countries with the highest burden of malaria worldwide, with an estimated 9.3 million cases in 2018, and constitutes a core target for the World Health Organization (WHO) and the Roll Back Malaria Partnership to End Malaria's country-led 'high burden to high impact' initiative. At the same time, the National Malaria Control Program (NMCP) of Mozambique seeks to accelerate elimination in the south, where transmission is lowest. NMCP is currently working with partners (Malaria Consortium, PMI, Global Fund) to set up a high-resolution surveillance system that can drive decision-making across all transmission strata through strengthening of routine data quality, data use and data to action packages. However, decisions become more complex as control reveals heterogeneity and better tools are required for a strategic use of information to drive impact. The overall objective of the study is to operationalize a functional malaria molecular surveillance (MMS) system that generates reliable and reproducible genomic data over time for programmatic decisions. The integration of genomic data into routine surveillance activities has the potential to increase the actionable intelligence for making programmatic decisions on the optimal mix of control and elimination measures in Mozambique by:

1. Informing drug and diagnostic choices through the monitoring of antimalarial drug resistance and diagnostic resistance (hrp2/3 deletions);
2. Targeting the reservoirs sustaining transmission through the use of transmission network models to quantify parasite importation, identify sources and characterize local transmission in near-elimination settings;
3. Improving stratification, monitoring and impact evaluations in different epidemiological and health system contexts through the use of measures of P. falciparum genetic diversity (routinely from positive cases) to supplement traditional surveillance, especially where it is sparse;
4. Using alternative, cost-effective, approaches targeting easy-access populations (e.g. pregnant women at antenatal care clinics) to monitor transmission and antimalarial/diagnostic resistance.

Conditions

  • Malaria,Falciparum
  • Malaria in Pregnancy
  • Malaria

Interventions

DIAGNOSTIC_TEST

LDH-based malaria rapid diagnostic test

Malaria testing using an LDH-based malaria rapid diagnostic test will be added to standard routine testing of suspected cases at health facilities

DIAGNOSTIC_TEST

Malaria rapid diagnostic test

All pregnant women attending their first routine antenatal visit will be tested for malaria using routine malaria rapid diagnostic tests

Sponsors & Collaborators

  • National Malaria Control Program, Mozambique

    collaborator UNKNOWN

  • Malaria Consortium

    collaborator OTHER

  • Barcelona Institute for Global Health

    collaborator OTHER

  • University of California, San Francisco

    collaborator OTHER

  • Centro de Investigacao em Saude de Manhica

    lead OTHER

Eligibility

Min Age
6 Months
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-10-12
Primary Completion
2023-12-31
Completion
2024-03-31

Countries

  • Mozambique

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05306067 on ClinicalTrials.gov